Immunovant, Inc. (IMVT)
32.70
+0.59
(+1.84%)
USD |
NASDAQ |
Oct 07, 12:42
Immunovant Net Income (Quarterly) : -153.22M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -153.22M |
| March 31, 2026 | -147.86M |
| December 31, 2025 | -110.64M |
| September 30, 2025 | -126.50M |
| June 30, 2025 | -120.61M |
| March 31, 2025 | -106.45M |
| December 31, 2024 | -111.12M |
| September 30, 2024 | -109.12M |
| June 30, 2024 | -87.15M |
| March 31, 2024 | -75.32M |
| December 31, 2023 | -51.42M |
| September 30, 2023 | -58.66M |
| June 30, 2023 | -73.94M |
| March 31, 2023 | -59.43M |
| Date | Value |
|---|---|
| December 31, 2022 | -63.23M |
| September 30, 2022 | -47.93M |
| June 30, 2022 | -40.37M |
| March 31, 2022 | -47.17M |
| December 31, 2021 | -41.38M |
| September 30, 2021 | -37.70M |
| June 30, 2021 | -30.47M |
| March 31, 2021 | -28.16M |
| December 31, 2020 | -31.78M |
| September 30, 2020 | -20.79M |
| June 30, 2020 | -26.71M |
| March 31, 2020 | -20.55M |
| December 31, 2019 | -11.30M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Roivant Sciences Ltd. | -290.61M |
| Moderna, Inc. | -782.00M |
| Altimmune, Inc. | -22.82M |
| Vertex Pharmaceuticals, Inc. | 1.100B |
| First Tracks Biotherapeutics, Inc. | -33.37M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 153.22M |
| EPS Diluted (Quarterly) | -0.7454 |
| Enterprise Value | 5.825B |
| Earnings Yield | -8.59% |
| Normalized Earnings Yield | -8.591 |